Myasthenia Gravid Clinical Trial
Official title:
A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis
Immunomodulation is effective in treating patients with myasthenia gravis (MG), but prior
studies have not adequately defined if plasma exchange (PLEX) in superior to intravenous
immunoglobulin (IVIG) in the treatment of myasthenia gravis. This study aimed to determine
if PLEX was superior to IVIG in the treatment of patients with myasthenia gravis.
Patients with MG requiring immunomodulation are randomized to IVIG or PLEX and treated with
a full course of immunomodulation. The quantitative myasthenia gravis score (QMGS) will be
evaluated as the primary efficacy parameter at day 14 to determine if PLEX is superior to
IVIG.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment